Genesis’ proprietary foundation model – Pearl – outperforms frontier models, including AlphaFold 3, on key benchmarks that predict utility in real-world drug discovery Pearl’s performance improved ...
This process is costly, time-consuming, and has a low success rate. KAIST researchers have developed an AI model that, using only information about the target protein, can design optimal drug ...
Researchers at Los Alamos National Laboratory have developed a new approach that addresses the limitations of generative AI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback